Scholar Rock Corrects Q4 Net Loss to $0.76/Share, Less Than Previously Reported
summarizeSummary
Scholar Rock issued a "CORRECTING and REPLACING" release for its fourth quarter and full-year 2025 financial results, revising its net loss per common share for Q4 2025 from an initial -$0.88 to -$0.76. This correction follows earlier news and SEC filings today that reported the company's Q4/FY25 results, including a widened net loss, a new $550 million non-dilutive debt facility, and a Complete Response Letter (CRL) from the FDA for its lead SMA drug, apitegromab. While the core business highlights and overall financial picture remain largely consistent with earlier reports, the revision to a key earnings metric like net loss per share is a material update for investors and analysts who may have acted on the previously reported figures. The correction itself is a positive adjustment, indicating a slightly better financial performance than initially stated. Investors will continue to monitor the company's progress on the apitegromab BLA resubmission following the FDA's constructive meeting with Catalent Indiana, as well as the EMA decision for the MAA in mid-2026.
At the time of this announcement, SRRK was trading at $45.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $22.71 to $49.82. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.